First-line immunotherapy using Wilms’ tumor protein 1 (WT1)-targeted dendritic cell vaccinations for malignant pleural mesothelioma

计划入组 30 人 · 首次发布于 2024 年 11 月 4 日

WT1 in Colorectal Adenocarcinoma

计划入组 60 人 · 首次发布于 2026 年 8 月 21 日

WT1 Peptid Vaccination in Carcinomas

计划入组 25 人 · 首次发布于 2005 年 9 月 12 日

WT1 protein-specific T-cell therapy(Memorial Sloan-Kettering Cancer Center)

WT1-W10

WT1-pTj

Protein Sciences Corporation

United States

HOUSE OF SUPPLEMENTS AUSTRALIA PTY LTD

Australia

Sanofi-Aventis Deutschland Gmbh

Sweden

SELLAS Life Sciences Receives Positive IDMC Recommendation to Continue Phase 3 REGAL Trial of Galinpepimut-S in AML

SELLAS Life Sciences Secures $31 Million Through Warrant Exercise to Advance Cancer Therapeutics Pipeline

SELLAS Life Sciences Announces R&D Day to Showcase Phase 3 AML Trial Results and CDK9 Inhibitor Program